WVE
$12.46
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company's medicines platform, PRISM combines multipl...
Recent News
How Strong Q4 Revenue Amid Deeper Losses At Wave Life Sciences (WVE) Has Changed Its Investment Story
In late February 2026, Wave Life Sciences Ltd. reported Q4 2025 results showing sales of US$17.24 million versus US$83.75 million a year earlier, alongside a net loss of US$53.18 million compared with net income of US$29.25 million in the prior-year quarter. Despite the wider full-year net loss of US$204.38 million and higher loss per share, investors focused on the company’s progress in obesity and RNA editing programs, including WVE-007 and WVE-006, and on quarterly revenue that exceeded...
Wave Life Sciences Teases Near-Term Obesity and RNA Editing Data as INLIGHT Readouts Near
Wave Life Sciences (NASDAQ:WVE) highlighted upcoming clinical catalysts across its obesity and RNA editing programs during a discussion hosted by Oppenheimer biotech analyst Cheng Li following the company’s fourth-quarter results. Company focus: oligonucleotide chemistry and genetically validated t
Wave Life Sciences Ltd. (WVE): A Bull Case Theory
We came across a bullish thesis on Wave Life Sciences Ltd. on X.com by @MoneyShow. In this article, we will summarize the bulls’ thesis on WVE. Wave Life Sciences Ltd.’s share was trading at $14.54 as of February 25th. Wave Life Sciences Ltd. (WVE) is emerging as a leading force in RNA-based therapeutics, leveraging its proprietary PRISM platform to target genetically validated disorders through RNA editing, silencing, […]
Wave Life Sciences Ltd. (WVE) Announces Fiscal Q4 and Full-Year 2025 Earnings
Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the best hot stocks under $20 to buy. Wave Life Sciences Ltd. (NASDAQ:WVE) released its fiscal Q4 and full-year 2025 earnings on February 26, reporting that it is on track for INLIGHT clinical data update in 1Q 2026, with fat loss similar to GLP-1 observed at three […]
WAVE Life Sciences Q4 Earnings Call Highlights
WAVE Life Sciences (NASDAQ:WVE) executives used the company’s fourth-quarter and full-year 2025 earnings call to highlight clinical progress in its obesity and RNA editing programs, outline upcoming data catalysts, and review year-end financial results. President and CEO Dr. Paul Bolno said 2025 del